| European Case Law Identifier: | ECLI:EP:BA:2013:T010809.20130214 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 14 February 2013 | ||||||||
| Case number: | T 0108/09 | ||||||||
| Application number: | 01917289.9 | ||||||||
| IPC class: | A61K 31/565 A61P 35/00 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | D | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Use of fulvestrant in the treatment of resistant breast cancer | ||||||||
| Applicant name: | AstraZeneca AB | ||||||||
| Opponent name: | Teva Pharmaceutical Industries Ltd. | ||||||||
| Board: | 3.3.02 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Added matter (no) Sufficiency of disclosure, novelty and inventive step (yes) |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t090108eu1.html
Date retrieved: 17 May 2021